D
Kura Oncology, Inc. KURA
$10.56 $0.343.33% NASDAQ
Recommendation
Prev Close
$10.22
Volume
1,729,380
Avg Vol (90D)
1,908,228
Market Cap
$889.32M
Dividend & Yield
--
52-Week Range
$5.41 - $12.49
P/E (TTM)
--
EPS (TTM)
-$2.48
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Kura Oncology (KURA) Gains Momentum as Barclays Sees Significant Potential in Ziftomenib Approval
12/16/2025 - Insider Monkey
Kura Oncology, Inc. (KURA) Discusses Ziftomenib Combination Data in Newly Diagnosed and Relapsed/Refractory NPM1-m and KMT2A-r AML - Slideshow
12/15/2025 - SeekingAlpha
Kura Oncology, Inc. (NASDAQ:KURA) Given Consensus Rating of "Moderate Buy" by Brokerages
12/15/2025 - MarketBeat
EcoR1 Capital LLC Boosts Stock Position in Kura Oncology, Inc. $KURA
12/13/2025 - MarketBeat
Kura Oncology (KURA, $10.46) price exceeded its 50-day Moving Average on December 11, 2025
12/12/2025 - Tickeron - Technical Analysis
Kura Oncology, Inc. $KURA Shares Sold by Armistice Capital LLC
12/12/2025 - MarketBeat
Insider Sell: Faheem Hasnain Sells 10,000 Shares of Kura Oncology Inc (KURA)
12/10/2025 - GuruFocus
Kura Oncology (KURA, $10.67) entered Downtrend as Momentum indicator drops below 0 level on Dec 09, 2025
12/10/2025 - Tickeron - Stocks
Kura Oncology (KURA, $10.67) price may climb as it broke lower Bollinger Band on Dec 09, 2025
12/10/2025 - Tickeron - Stocks
BTIG Sticks to Their Hold Rating for Kura Oncology (KURA)
12/10/2025 - TipRanks Financial Blog
Kura Oncology (NASDAQ:KURA) Shares Down 4.6% - What's Next?
12/9/2025 - MarketBeat
Kura Oncology (KURA, $11.64) Moving Average Convergence Divergence (MACD) Histogram turned negative on December 8, 2025
12/9/2025 - Tickeron - Stocks
Kura Oncology Inc ASH Update Call Transcript
12/9/2025 - GuruFocus
Kura Oncology, Inc. (KURA) Discusses Ziftomenib Combination Data in Newly Diagnosed and Relapsed/Refractory NPM1-m and KMT2A-r AML Transcript
12/8/2025 - SeekingAlpha
Kura Oncology, Inc. (KURA) Discusses Ziftomenib Combination Data in Newly Diagnosed and Relapsed/Refractory NPM1-m and KMT2A-r AML Transcript
12/8/2025 - Seeking Alpha: Transcripts
Kura Oncology (KURA) Reports Promising AML Trial Results
12/8/2025 - GuruFocus
Kura Oncology, Kyowa Kirin reveal Komsifti combo data for AML
12/8/2025 - Seeking Alpha - Healthcare
Kura Oncology (KURA) Reveals Positive Leukemia Treatment Data
12/8/2025 - GuruFocus
Kura Oncology, Kyowa Kirin report combination data for KOMZIFTI with ven/aza
12/8/2025 - TipRanks Financial Blog
Kura Oncology, Kyowa Kirin report combination data for KOMZIFTI with ven/aza
12/8/2025 - The Fly
Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML
12/8/2025 - Globe Newswire
Kura Oncology, Inc. $KURA Shares Sold by Walleye Capital LLC
12/8/2025 - MarketBeat
Kura Oncology (KURA, $11.97) Moving Average Convergence Divergence (MACD) Histogram turned positive on December 3, 2025
12/5/2025 - Tickeron - Technical Analysis
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points
12/4/2025 - CNW Group - News Releases
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points
12/4/2025 - PR Newswire
Income Statement
Total Revenue (TTM)
$104.03M
EBITDA (TTM)
-$238.99M
EBIT (TTM)
-$239.82M
Net Income (TTM)
-$216.88M
Balance Sheet
Total Assets (Q)
$649.38M
Total Debt (Q)
$19.47M
Total Liabilities (Q)
$406.84M
Book Value Per Share (Q)
$2.79
Cash Flow
Cash from Operations (TTM)
$87.80M
Cash from Investing (TTM)
-$43.46M
Cash from Financing (TTM)
$1.46M
Net Change in Cash (TTM)
$45.81M
Filings
Filing Date
Tuesday, November 4, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Feb 23 and 27 (est)
Price History
Loading...
Beta
1.94
7-Day Total Return
-11.85%
30-Day Total Return
2.82%
60-Day Total Return
28.00%
90-Day Total Return
77.18%
Year to Date Total Return
21.66%
1-Year Total Return
9.66%
2-Year Total Return
-8.97%
3-Year Total Return
-23.37%
5-Year Total Return
-74.46%
52-week Low
Apr 07, 2025 - $5.41
52-week High
Nov 14, 2025 - $12.49
Valuation
Market Cap
$889.32M - Small Cap
Enterprise Value
$359.12M
Price/Sales (TTM)
8.61
Price/Book (Q)
3.67
Dividends and Shares
Shares Outstanding
87.65
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
kuraoncology.com
Phone Number
858 500 8800
Address
12730 High Bluff Drive
San Diego, CA 92130
Country
United States
Year Founded
--
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its lead product candidate includes ziftomenib, a selective investigational... more
NASDAQ 12/15/2025 4:00PM Eastern Quotes delayed